Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.370
-0.005 (-0.21%)
Oct 30, 2026, 4:08 PM HKT

HKG:1349 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-103.09-157.4439.73108.63138213.3
Depreciation & Amortization
55.361.0374.259.9380.9760.85
Other Amortization
23.3517.628.022.31.220.96
Loss (Gain) From Sale of Assets
-0.22-0.22-0.03-0.3-1.92-1.78
Asset Writedown & Restructuring Costs
0.350.354.425.781.010.35
Loss (Gain) From Sale of Investments
9.859.8510.414.351.28-20.76
Stock-Based Compensation
----1.847.6964.97
Provision & Write-off of Bad Debts
-23.85-23.85-8.9323.9-2.415.78
Other Operating Activities
-19.751.82.496.23-0.28-6.13
Change in Accounts Receivable
213.27213.27114.05-10.47-89.73-95.37
Change in Inventory
12.5312.53-5.86-6.57-5.840.32
Change in Accounts Payable
1.461.46-236.31-74.0548.7272.56
Change in Unearned Revenue
3.133.1313.69-31.89-6.76-9.89
Operating Cash Flow
174.19141.4-16.5171.02165.27268.9
Operating Cash Flow Growth
16.42%---57.03%-38.54%137.96%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-26.27-32.37-42.67-98.97-87.3-120.12
Sale of Property, Plant & Equipment
0.080.830.640.681.441.71
Divestitures
-----6.34
Investment in Securities
15.2515.2518.1552.91-10.88-243.6
Other Investing Activities
-1.064.081.74---
Investing Cash Flow
-12.01-12.21-22.14-45.38-96.75-355.67

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----101-
Total Debt Issued
----101-
Long-Term Debt Repaid
--6.81-7.93-109.38-9.52-7.5
Lease Payments
-6.81-6.81-7.93-9.38-9.52-7.5
Total Debt Repaid
-6.81-6.81-7.93-109.38-9.52-7.5
Net Debt Issued (Repaid)
-6.81-6.81-7.93-109.3891.48-7.5
Issuance of Common Stock
---66.86--
Repurchase of Common Stock
-----8.7-40.82
Common Dividends Paid
--31.1-93.29-76.15-71.04-52.15
Other Financing Activities
1.01--0.05-0.31-0.14-0.69
Financing Cash Flow
-5.8-37.91-101.27-118.9811.61-101.16

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-1.05-0.490.32-0.070.29-0.07
Net Cash Flow
155.3490.79-139.61-93.4180.42-188.01

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
147.92109.03-59.18-27.9577.96148.78
Free Cash Flow Growth
48.97%----47.60%110.76%
Free Cash Flow Margin
22.26%15.90%-8.34%-3.29%7.56%13.05%
Free Cash Flow Per Share
0.130.10-0.06-0.030.080.14
Levered Free Cash Flow
177.22153.42-96.4618.6486.7116.02
Unlevered Free Cash Flow
177.31153.83-96.0920.5687.67116.68
Free Cash Flow After Leases
141.11102.22-67.12-37.3368.45141.28

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
63.5949.5449.2133.5368.6668.12
Change in Working Capital
232.25232.25-146.83-137.96-60.29-48.63